ANGO Latest Report

Financial Performance

AngioDynamics reported a total operating revenue of RMB72,004,000 as of February 28, 2025, indicating potential difficulties in its operations. The operating loss of -9,974,000 RMB suggests that sales revenue failed to cover costs and expenses. The high marketing, sales, and general administrative expenses of RMB38,592,000 may have increased the company's financial pressure. Although the company invested RMB6,913,000 in research and development to promote new product development, it failed to translate into revenue in the short term.

Key Financial Data

1. The operating revenue of -9,974,000 RMB indicates poor sales performance.

2. The operating expenses of RMB38,592,000 are high, increasing the company's financial burden.

3. The research and development expenses of RMB6,913,000 show the company's emphasis on innovation, but failed to bring short-term benefits.

4. The pre-tax profit of -4,409,000 RMB indicates poor overall financial condition.

Peer Comparison

1. Industry-wide analysis: The medical device industry faced intense competition and market demand changes in 2025, with significant fluctuations in overall operating revenue, especially during the uneven post-pandemic recovery, which may have increased the company's financial pressure.

2. Peer evaluation analysis: AngioDynamics' operating revenue performance is relatively weak, especially the negative operating revenue reflecting its lack of competitiveness in the market. Comparing operating revenues with major competitors can assess AngioDynamics' market position and industry trends.

Summary

AngioDynamics faces significant financial pressure in 2025, with negative operating revenue, indicating challenges in market competition. Although the company has invested in research and development and innovation, it has failed to translate into significant revenue in the short term, and needs to pay attention to its future profitability recovery.

Opportunities

1. AngioDynamics' new product NanoKnife system has received positive market feedback, helping to boost sales.

2. The sales growth of Auryon and AngioVac indicates increasing market demand for its products.

3. With the overall demand for medical devices increasing, AngioDynamics can enhance its competitiveness through market adaptability and innovation.

Risks

1. Negative operating revenue indicates the company's shortcomings in sales and market adaptation, requiring caution against continued losses.

2. High operating expenses may increase financial pressure, affecting the company's liquidity and development.

3. Intense competition and changes in the industry environment may further affect the company's market share and profitability.